IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis

Riener,Marc‑Oliver; Hoegel,Josef; Iro,Heinrich; Hartmann,Arndt; Agaimy,Abbas

doi:10.3892/ol.2017.6352

IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis

Authors:
- Marc‑Oliver Riener
- Josef Hoegel
- Heinrich Iro
- Arndt Hartmann
- Abbas Agaimy
View Affiliations

Affiliations: Institute of Pathology, University Hospital, Friedrich‑Alexander University Erlangen‑Nuremberg, D-91054 Erlangen, Germany, Institute of Human Genetics, University Hospital Ulm, D-89081 Ulm, Germany, Department of Otorhinolaryngology, Head & Neck Surgery, Friedrich‑Alexander University Erlangen‑Nuremberg, University Hospital, D-91054 Erlangen, Germany
Published online on: June 8, 2017 https://doi.org/10.3892/ol.2017.6352
Pages: 1665-1670

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of p16 has been established as a good surrogate marker for high-risk human papillomavirus (HPV) infection in oropharyngeal squamous cell carcinoma (OPSCC) patients, and it has been associated with an improved prognosis, irrespective of the actual HPV status. Conversely, the human insulin‑like growth factor II mRNA binding protein 3 (IMP3) has been related to aggressiveness in several types of tumors. The aim of the present study was to investigate and compare p16 and IMP3 as markers of favorable and unfavorable behavior, respectively, in head and neck SCC (HNSCC), with particular reference to the HPV status. Both markers were analyzed by immunohistochemical analysis of 156 HNSCC samples originating from the oropharynx (n=81), oral cavity (n=44), larynx (n=15), hypopharynx (n=10) and nasopharynx (n=6). The HPV status was examined in a randomly selected representative subcohort (n=38) using polymerase chain reaction. Of the 156 HNSCC samples, 81 (51.9%) and 54 (34.6%) were positive for IMP3 and p16, respectively. IMP3 expression (P=0.022), p16 expression (P<0.001) and the combination of these markers (P<0.001) were significantly associated with tumor site. In particular, 69/81 (85%) OPSCC samples were positive for either one or both markers compared with 36/75 (48%) SCC samples from other sites. p16 expression was significantly associated with HPV infection (P=0.017) and a trend towards a negative association between IMP3 expression and HPV infection was observed (P=0.053). The results of the present study suggested that IMP3 and p16 are more frequently expressed in OPSCC compared with other HNSCCs. The prognostic impact of IMP3 on OPSCC remains to be investigated in a larger series with an extended follow‑up period.

View Figures

View References

1	Barnes L, Eveson JW, Reichart P and Sidransky D: World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon, France: IARC Press; pp. 46–50. 2005
2	Jo VY, Mills SE, Stoler MH and Stelow EB: Papillary squamous cell carcinoma of the head and neck: Frequent association with human papillomavirus infection and invasive carcinoma. Am J Surg Pathol. 33:1720–1724. 2009. View Article : Google Scholar : PubMed/NCBI
3	Benevolo M, Mottolese M, Marandino F, Vocaturo G, Sindico R, Piperno G, Mariani L, Sperduti I, Canalini P, Donnorso RP and Vocaturo A: Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol. 19:384–391. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q and El-Mofty SK: p16 positive oropharyngeal squamous cell carcinoma: An entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 34:1088–1096. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mehrad M, Carpenter DH, Chernock RD, Wang H, Ma XJ, Luo Y, Luo J, Lewis JS Jr and El-Mofty SK: Papillary squamous cell carcinoma of the head and neck: Clinicopathologic and molecular features with special reference to human papillomavirus. Am J Surg Pathol. 37:1349–1356. 2013. View Article : Google Scholar : PubMed/NCBI
6	Cai C, Chernock RD, Pittman ME, El-Mofty SK, Thorstad WL and Lewis JS Jr: Keratinizing-type squamous cell carcinoma of the oropharynx: p16 overexpression is associated with positive high-risk HPV status and improved survival. Am J Surg Pathol. 38:809–815. 2014. View Article : Google Scholar : PubMed/NCBI
7	Müeller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M, Beger HG, et al: Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 14:2729–2733. 1997. View Article : Google Scholar : PubMed/NCBI
8	Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G and Gress TM: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 88:95–99. 1999. View Article : Google Scholar : PubMed/NCBI
9	Nielsen FC, Nielsen J and Christiansen J: A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 234:93–99. 2001. View Article : Google Scholar : PubMed/NCBI
10	Monk D, Bentley L, Beechey C, Hitchins M, Peters J, Preece MA, Stanier P and Moore GE: Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet. 39:575–581. 2002. View Article : Google Scholar : PubMed/NCBI
11	Liao B, Hu Y, Herrick DJ and Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005. View Article : Google Scholar : PubMed/NCBI
12	Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J and Nielsen FC: RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 25:1456–1468. 2006. View Article : Google Scholar : PubMed/NCBI
13	Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z and Kwon ED: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI
14	Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL and Kwon ED: Oncofetal protein IMP3: A novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 112:2676–2682. 2008. View Article : Google Scholar : PubMed/NCBI
15	Li C, Rock KL, Woda BA, Jiang Z, Fraire AE and Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: An immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 20:242–247. 2007. View Article : Google Scholar : PubMed/NCBI
16	Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV and Fischer AH: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: Diagnostic significance and clinicopathologic correlations. Mod Pathol. 20:1263–1268. 2007. View Article : Google Scholar : PubMed/NCBI
17	Lu D, Vohra P, Chu PG, Woda B, Rock KL and Jiang Z: An oncofetal protein IMP3: A new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 33:521–525. 2009. View Article : Google Scholar : PubMed/NCBI
18	Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA and Xu H: IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 21:431–437. 2008. View Article : Google Scholar : PubMed/NCBI
19	Pryor JG, Simon RA, Bourne PA, Spaulding BO, Scott GA and Xu H: Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas. Hum Pathol. 40:238–243. 2009. View Article : Google Scholar : PubMed/NCBI
20	Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL and Jiang Z: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 14:1701–1706. 2008. View Article : Google Scholar : PubMed/NCBI
21	Xu H, Bourne PA, Spaulding BO and Wang HL: High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 38:555–563. 2007. View Article : Google Scholar : PubMed/NCBI
22	Strehl JD, Hoegel J, Hornicek I, Hartmann A and Riener MO: Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa. Int J Clin Exp Pathol. 7:2091–2101. 2014.PubMed/NCBI
23	Wachter DL, Kristiansen G, Soll C, Hellerbrand C, Breuhahn K, Fritzsche F, Agaimy A, Hartmann A and Riener MO: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology. 60:278–286. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wachter DL, Schlabrakowski A, Hoegel J, Kristiansen G, Hartmann A and Riener MO: Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol. 35:873–877. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL and Dresser K: KOC (K homology domain containing protein overexpressed in cancer): A novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 29:188–195. 2005. View Article : Google Scholar : PubMed/NCBI
26	Zhao H, Mandich D, Cartun RW and Ligato S: Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol. 35:700–704. 2007. View Article : Google Scholar : PubMed/NCBI
27	Riener MO, Fritzsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W and Kristiansen G: IMP3 expression in lesions of the biliary tract: A marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol. 40:1377–1383. 2009. View Article : Google Scholar : PubMed/NCBI
28	Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL and Khan A: IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol. 40:1528–1533. 2009. View Article : Google Scholar : PubMed/NCBI
29	Lin CY, Chen ST, Jeng YM, Yeh CC, Chou HY, Deng YT, Chang CC and Kuo MY: Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 40:699–705. 2011. View Article : Google Scholar : PubMed/NCBI
30	Li S, Cha J, Kim J, Kim KY, Kim HJ, Nam W and Cha IH: Insulin-like growth factor II mRNA-binding protein 3: A novel prognostic biomarker for oral squamous cell carcinoma. Head Neck. 33:368–374. 2011.PubMed/NCBI
31	Kim KY, Li S, Cha JD, Zhang X and Cha IH: Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck. 34:929–936. 2012. View Article : Google Scholar : PubMed/NCBI
32	Li HG, Han JJ, Huang ZQ, Wang L, Chen WL and Shen XM: IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma. J Craniofac Surg. 22:2022–2025. 2011. View Article : Google Scholar : PubMed/NCBI
33	Clauditz TS, Wang CJ, Gontarewicz A, Blessmann M, Tennstedt P, Borgmann K, Tribius S, Sauter G, Dalchow C, Knecht R, et al: Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J Oral Pathol Med. 42:125–132. 2013. View Article : Google Scholar : PubMed/NCBI
34	Chen K, Cornejo KM, Ye W, Wu Q, Liang J and Jiang Z: Oncofetal protein IMP3: A new diagnostic biomarker for laryngeal carcinoma. Hum Pathol. 44:2126–2131. 2013. View Article : Google Scholar : PubMed/NCBI
35	Knör M, Tziridis K, Agaimy A, Zenk J and Wendler O: Human Papillomavirus (HPV) Prevalence in Nasal and Antrochoanal Polyps and association with clinical data. PLoS One. 10:e01417222015. View Article : Google Scholar : PubMed/NCBI
36	Ismerim AB, Ferreira SV, Lessa AM, Júnior AS Pereira, Gurgel CA, Coutinho-Camillo CM, Soares FA, Vilas-Bôas DS, Vidal MT and Santos JN: Insulin-like growth factor II messenger RNA-binding protein 3 in Salivary Gland tumors. Appl Immunohistochem Mol Morphol. 24:422–426. 2016. View Article : Google Scholar : PubMed/NCBI
37	Wei Q, Fu B, Liu J, Xu J and Zhao T: Combined detection of p16(INK4a) and IMP3 increase the concordance rate between cervical cytologic and histologic diagnosis. Int J Clin Exp Pathol. 6:1549–1557. 2013.PubMed/NCBI
38	Del Gobbo A, Bonoldi E, Cribiù FM, Franceschetti I, Matinato C, Fiori S, Gianelli U and Bosari S: Insulin-like growth factor II mRNA binding protein 3 (IMP3) expression in cervical intraepithelial neoplasia and its relationship with HIV-infection status. Sex Health. 12:22–26. 2015. View Article : Google Scholar : PubMed/NCBI
39	Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, et al: Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 21:312–321. 2015. View Article : Google Scholar : PubMed/NCBI